What is STRATEOS?
Strateos operates at the critical intersection of biotechnology and software engineering, providing a sophisticated Cloud Lab Automation-as-a-Service platform. By enabling scientists to design, execute, and analyze complex experiments remotely, the company effectively removes the physical constraints of traditional laboratory environments. This paradigm shift toward automated, reproducible research is essential for modern drug discovery and synthetic biology, positioning Strateos as a foundational player in the digital transformation of the life sciences sector. The company's platform leverages advanced robotics to ensure that scientific inquiry is not only faster but also more consistent and scalable.
How much funding has STRATEOS raised?
STRATEOS has raised a total of $64.6M across 2 funding rounds:
Series A
$8.5M
Series B
$56.1M
Series A (2015): $8.5M with participation from AME Cloud Ventures, MITS Fund, Wei Guo, Silicon Valley Bank, Holtzbrinck Digital, Paul Buchheit, DCVC, UpHonest Capital, IA Ventures, and Y Combinator
Series B (2021): $56.1M led by Black Diamond Ventures, Lux Capital, DCVC Management, Ally Bridge Group, and Lilly
Key Investors in STRATEOS
Lux Capital
Lux Capital is a New York based venture capital firm that raises dedicated funds to invest in earlystage and growthstage companies at the intersection of science and technology, backing founders in frontier areas such as AI, robotics, space, defense, biotechnology, and advanced materials from seed through IPO or acquisition.
DCVC Management
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling some of the world's most challenging problems, focusing on leveraging artificial intelligence to unlock potential across sectors including biotechnology and agriculture.
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm that specializes in high-impact life science innovation, managing over $6 billion in transactions and focusing on both private and public equity strategies to address unmet medical needs.
What's next for STRATEOS?
Following this major strategic investment, Strateos is well-positioned to expand its operational capacity and deepen its technological moat. The company is expected to focus on scaling its robotic infrastructure and enhancing its software suite to support increasingly complex biological research requirements. By leveraging the expertise of its deep-tech and healthcare-focused backers, Strateos aims to solidify its role as the primary operating system for the next generation of life science discovery, potentially setting new industry standards for experimental efficiency and data integrity in the global biotech market.
See full STRATEOS company page
